Table 2.
Study no. | Author | Country | Year of publication | CDI episode | Treatment regimens compared | Most cost-effective treatment |
---|---|---|---|---|---|---|
Initial C. difficile infection | ||||||
1 | Stranges et al. 77 | US | 2013 | Initial | Vancomycin versus fidaxomicin | Fidaxomicin for mild-moderate CDI Vancomycin for severe CDI |
2 | Varier et al. 78 | US | 2014 | Initial | Vancomycin versus metronidazole versus FMT | FMT |
3 | Wagner et al. 79 | Canada | 2014 | Initial | Vancomycin versus fidaxomicin | Vancomycin |
4 | Nathwani et al. 80 | UK | 2014 | Initial | Vancomycin versus fidaxomicin | Fidaxomicin |
5 | Marković et al. 81 | Serbia | 2014 | Initial | Vancomycin versus fidaxomicin | Fidaxomicin |
6 | Rubio-Terres et al. 82 | Spain | 2015 | Initial | Vancomycin versus extended-pulsed fidaxomicin | Extended-pulsed fidaxomicin |
7 | Watt et al. 83 | Germany | 2016 | Initial | Vancomycin versus fidaxomicin | Fidaxomicin |
8 | Watt et al. 84 | France | 2017 | Initial | Vancomycin versus fidaxomicin | Fidaxomicin |
9 | Rajasingham et al. 75 | US | 2020 | Initial | Vancomycin versus fidaxomicin versus metronidazole | Fidaxomicin for non-severe CDI Vancomycin for severe CDI |
Recurrent C. difficile infection | ||||||
1 | Konijeti et al. 85 | US | 2014 | Recurrent | Vancomycin versus fidaxomicin versus metronidazole versus FMT | FMT by colonoscopy |
2 | Zowall et al. 86 | Canada | 2014 | Recurrent | Standard antibiotic regimens versus FMT | FMT |
3 | Varier et al. 87 | US | 2015 | Recurrent | Tapered vancomycin versus FMT | FMT |
4 | Lapointe-Shaw et al. 88 | Canada | 2016 | Recurrent | Vancomycin versus fidaxomicin versus metronidazole versus FMT by enema versus FMT by colonoscopy versus FMT by NGT | FMT by colonoscopy |
5 | Merlo et al. 89 | Australia | 2016 | Recurrent | Vancomycin versus FMT | FMT |
6 | Waye et al. 90 | Canada | 2016 | Recurrent | Early FMT versus Delayed FMT | Early FMT |
7 | Baro et al. 91 | France | 2017 | Recurrent | Pulse-tapered vancomycin versus fidaxomicin versus FMT | FMT by enema |
8 | Prabhu et al. 92 | US, UK | 2017 | Recurrent | Bezlotuxumab versus placebo | Bezlotuxumab |
9 | Jiang et al. 93 | China | 2018 | Recurrent | Vancomycin versus ribotype-guided FMT | Ribotype-guided FMT |
10 | Abdali et al. 94 | UK | 2020 | Recurrent | Vancomycin versus fidaxomicin versus FMT | FMT by NGT |
11 | Rajasingham et al. 75 | US | 2020 | Recurrent | Vancomycin versus fidaxomicin versus metronidazole versus FMT | Fidaxomicin for first recurrence FMT for subsequent recurrences |
12 | You et al. 95 | China | 2020 | Recurrent CDI in IBD patients | Vancomycin versus fidaxomicin versus vancomycin plus bezlotuxumuab versus FMT | FMT |
CDI, Clostridiodes difficile infection; FMT, fecal microbiota transplantation; IBD, inflammatory bowel disease; NGT, nasogastric tube.